Management of Hepatitis C Infection

  • Authors: Jordan J. Feld, MD, MPH; Hemant Shah, MD, MScCH HPTE (More Info)
  • Editor In Chief: Stefan Zeuzem, MD
  • Last Reviewed: 7/24/18 (What's New)

Summary

  • High SVR12 rates observed with 8 or 12 weeks of glecaprevir/pibrentasvir with or without ribavirin in phase II and III trials
    • SURVEYOR-I/II: SVR12 83% to 100% in genotype 1-6 HCV infection[Kwo 2017a]
    • ENDURANCE-1: SVR12 99% to 100% in genotype 1 HCV infection[Zeuzem 2018]

Action required